Search
for

    GlossaryInosiplex

    antiviral drug that boosts the immune system

    Inosiplex, also known as Isoprinosine or Methisoprinol, is an antiviral and immunomodulatory drug. It is used to enhance the body's immune response and is often prescribed for viral infections such as herpes simplex and certain types of influenza. It works by stimulating the activity of white blood cells and increasing the production of cytokines, which are crucial for fighting off infections.

    Related Terms

    Research

    5 / 34 results
      Alopecia Areata: An Evidence-Based Treatment Update

      research Alopecia Areata: An Evidence-Based Treatment Update

      72 citations , July 2014 in “American journal of clinical dermatology”
      Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.
      Alopecia Areata: A Review of Treatments and Their Efficacy

      research Alopecia Areata

      49 citations , November 1992 in “Archives of dermatology”
      Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.

      research The treatment of alopecia areata.

      21 citations , September 1987 in “PubMed”
      Corticosteroid injections are the most effective treatment for alopecia areata.
      Dermatologic Therapy: December 1986 to December 1987

      research Dermatologic therapy: December 1986 to December 1987

      July 1988 in “Journal of The American Academy of Dermatology”
      Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.

    Community Join

    5 / 1000+ results

      community The New, Improved CB-03-01/Setipiprant Group Buy

       27 upvotes 9 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

      community Allergan recruiting for Setipiprant trial in the US

       13 upvotes 8 years ago
      The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.